At least to the San Jose Mercury News, he is:
Though it won’t be on the
same epic scale as a Jackie Robinson or a Muhammad Ali, who sacrificed
considerable parts of themselves to bear necessary torches, Lincecum’s
contribution will stand as part of another movement.
marijuana is fully decriminalized and legalized sometime in the next 20
years, sports figures will be among the many whose exceptional
accomplishments will have given testimony on its behalf.
Among the greats cited alongside Linceucm in the pot Hall of Fame: Phil Jackson, Kareem Abdul-Jabbar, Robert Parish, Randy Moss, one of the greatest wide receivers in NFL
history, and Michael Phelps. The editorial goes so far as to say that between his slacker looks and his apparent love of weed, Lincecum is poised to be a marketing piece for Major League Baseball as it attempts to court younger fans.
Whatever. I don’t judge Lincecum at all. I’m a live and let live kind of guy when it comes to such things. Glass houses and stones and all of that. But I know one thing: no matter how forward thinking and cutting edge the people who write these kind of editorials think themselves to be, we won’t truly be in the brave new world to which they aspire until the day comes when an athlete finds himself in Lincecum’s situation . . .and no one cares at all. Because in the grand scheme of things — even the scheme having to do with the decriminalization of weed — this is pretty meaningless.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.